Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks .

What is Regeneron Pharmaceuticals' stock price target for 2024?

20 Wall Street analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $720.00 to $1,189.00. On average, they anticipate the company's share price to reach $976.41 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts .

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the start of the year. Since then, REGN shares have increased by 2.1% and is now trading at $896.82. View the best growth stocks for 2024 here .

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our REGN earnings forecast .

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Friday, February, 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a trailing twelve-month return on equity of 17.61%. Regeneron Pharmaceuticals's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $10.96 EPS. Read the conference call transcript .

What ETFs hold Regeneron Pharmaceuticals' stock?

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include iShares Biotechnology ETF (IBB) , Invesco Nasdaq Biotechnology ETF (IBBQ) , VanEck Biotech ETF (BBH) , ProShares Ultra Nasdaq Biotechnology (BIB) , Invesco Pharmaceuticals ETF (PJP) , Invesco Biotechnology & Genome ETF (PBE) , iShares Genomics Immunology and Healthcare ETF (IDNA) and American CenturyFocused Dynamic Growth ETF (FDG) .

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com . Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , Netflix (NFLX) , Tesla (TSLA) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , Walt Disney (DIS) , Micron Technology (MU) , Advanced Micro Devices (AMD) and Salesforce (CRM) .

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Global Assets Advisory LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Perpetual Ltd (0.08%), Allspring Global Investments Holdings LLC (0.05%), Atwood & Palmer Inc. (0.04%) and State of Michigan Retirement System (0.03%). Insiders that own company stock include Andrew J Murphy , Arthur F Ryan, Arthur F Ryan , Bonnie L Bassler, Bonnie L Bassler , Christine A Poon , Christopher R Fenimore , George L Sing , George Yancopoulos , Huda Y Zoghbi , Joseph J Larosa , Joseph L Goldstein, Joseph L Goldstein , Leonard S Schleifer , Marc Tessier-Lavigne , Marion Mccourt , Michael S Brown , N Anthony Coles , Neil Stahl , P Roy Vagelos , Plew Daniel P Van, Plew Daniel P Van , Robert E Landry and Robert E Landry . View institutional ownership trends .

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC. Read More

NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free Regn Stock Alerts

$896.82

+2.83 (+0.32%)

(As of 04/19/2024 ET)

Compare

Today's Range: $891.46
▼
$920.73
50-Day Range: $893.99
▼
$993.35
52-Week Range: $684.80
▼
$998.33

Volume: 507,464 shs
Average Volume: 495,118 shs
Market Capitalization: $98.43 billion

P/E Ratio: 25.81
Dividend Yield: N/A
Price Target: $976.41

Get Regeneron Pharmaceuticals alerts:

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.70 Rating Score
Upside/Downside: 8.9% Upside
$976.41 Price Target
Short Interest: Healthy
1.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.69
Upright™ Environmental Score
News Sentiment: 0.24
Based on 26 Articles This Week
Insider Trading: Selling Shares
$13.12 M Sold Last Quarter
Proj. Earnings Growth: 3.99%
From $38.59 to $40.13 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.62 out of 5 stars

Medical Sector

246th out of 911 stocks

Pharmaceutical Preparations Industry

99th out of 411 stocks

2.4

Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 15 buy ratings, 4 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.29% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Regeneron Pharmaceuticals has recently increased by 2.16%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

2.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Regeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Regeneron Pharmaceuticals is -2.69.

2.4

News and Social Media Coverage

News Sentiment
Regeneron Pharmaceuticals has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 26 news articles for Regeneron Pharmaceuticals this week, compared to 14 articles on an average week.
Search Interest
Only 17 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.
MarketBeat Follows
20 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,124,641.00 in company stock.
Percentage Held by Insiders
Only 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to grow by 3.99% in the coming year, from $38.59 to $40.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 25.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.26.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 25.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 222.74.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 2.60. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

REGN Stock News Headlines

April 19, 2024 | finance.yahoo.com

Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution

April 19, 2024 | americanbankingnews.com

UBS Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 18, 2024 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) and Oragenics (NYSE:OGEN) Critical Review

April 17, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

April 17, 2024 | markets.businessinsider.com

Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN)

April 17, 2024 | benzinga.com

If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today

April 16, 2024 | msn.com

Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 16, 2024 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Receives "Neutral" Rating from Cantor Fitzgerald

April 15, 2024 | finance.yahoo.com

Regeneron to defend against DOJ complaint on drug-price manipulation

April 15, 2024 | finance.yahoo.com

UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation

April 15, 2024 | reuters.com

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

April 14, 2024 | americanbankingnews.com

Bank of America Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $720.00

April 14, 2024 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Lifted to "Strong-Buy" at StockNews.com

April 13, 2024 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 2.6%

April 13, 2024 | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts

April 12, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)

April 12, 2024 | markets.businessinsider.com

Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views

April 11, 2024 | msn.com

Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug

April 11, 2024 | investors.com

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

April 11, 2024 | msn.com

US accuses Regeneron of fraudulent price reporting for eye drug

April 11, 2024 | finance.yahoo.com

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

April 11, 2024 | finance.yahoo.com

These Stocks Are Moving the Most Today: CarMax, Fastenal, Alpine Immune, Nike, Robinhood, Constellation Brands, and More

April 11, 2024 | investopedia.com

Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch

April 11, 2024 | proactiveinvestors.com

Regeneron Pharma falls after US government alleges fraud

April 10, 2024 | marketwatch.com

Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea

See More Headlines

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/02/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:REGN
CUSIP: 75886F10
CIK: 872589
Web: www.regeneron.com
Phone: (914) 847-7000
Fax: 914-347-2113
Employees: 13,450
Year Founded: 1988

Price Target and Rating

Average Stock Price Target: $976.41
High Stock Price Target: $1,189.00
Low Stock Price Target: $720.00
Potential Upside/Downside: +9.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.70
Research Coverage: 20 Analysts

Profitability

EPS (Most Recent Fiscal Year): $34.75
Trailing P/E Ratio: 25.72
Forward P/E Ratio: 23.16
P/E Growth: 2.6
Net Income: $3.95 billion
Net Margins: 30.14%
Pretax Margin: 32.01%
Return on Equity: 17.61%
Return on Assets: 13.76%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 5.69
Quick Ratio: 4.94

Sales & Book Value

Annual Sales: $13.12 billion
Price / Sales: 7.48
Cash Flow: $42.91 per share
Price / Cash Flow: 20.83
Book Value: $236.63 per share
Price / Book: 3.78

Miscellaneous

Outstanding Shares: 109,760,000
Free Float: 100,070,000
Market Cap: $98.10 billion
Optionable: Optionable
Beta: 0.11

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Leonard S. Schleifer M.D. (Age 71)
Ph.D., Co-Founder, President, CEO & Co-Chairman
Comp: $7M
Dr. George D. Yancopoulos M.D. (Age 64)
Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman
Comp: $6.59M
Dr. Andrew J. Murphy Ph.D. (Age 65)
Executive Vice President of Research
Comp: $1.62M
Mr. Daniel P. Van Plew (Age 51)
Executive VP and GM of Industrial Operations & Product Supply
Comp: $1.95M
Ms. Marion E. McCourt (Age 64)
Executive Vice President of Commercial
Comp: $1.5M
Mr. Christopher R. Fenimore CPA (Age 53)
Senior VP of Finance & CFO
Ms. Patrice Gilooly
Senior Vice President of Quality Assurance & Operations
Mr. Bob McCowan
Senior VP of IT & Chief Information Officer
Mr. Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis
Mr. Joseph J. LaRosa (Age 65)
Executive VP, General Counsel & Secretary
Comp: $1.75M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

Regeneron Pharmaceuticals has a diverse product portfolio, including innovative medicines like EYLEA and Dupixent, which have shown significant success in treating various diseases.
The company's ongoing research and development efforts demonstrate a commitment to advancing healthcare solutions and potentially introducing new breakthrough treatments.
Regeneron's collaboration with other pharmaceutical companies and research institutions enhances its capabilities for developing cutting-edge therapies and expanding its market reach.
Recent positive regulatory approvals and clinical trial results have boosted investor confidence in the company's future growth prospects and revenue potential.
Despite market fluctuations, Regeneron's stock price has shown resilience and maintained a relatively stable performance, offering investors a sense of security and potential long-term returns.

Cons

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

Regeneron Pharmaceuticals faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability over time.
The company's heavy reliance on a few key products, such as EYLEA and Dupixent, for a significant portion of its revenue poses a risk in case of unexpected market changes or regulatory challenges.
Fluctuations in research and development outcomes or delays in product launches could affect investor sentiment and lead to short-term volatility in the stock price.
Regeneron's exposure to regulatory changes, pricing pressures, and intellectual property disputes within the healthcare sector may create uncertainties for investors regarding the company's future financial performance.
Investing in biotechnology companies like Regeneron Pharmaceuticals involves inherent risks related to clinical trial failures, patent expirations, and market unpredictability, which could impact investment returns.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.
What is Regeneron Pharmaceuticals' stock price target for 2024?: 20 Wall Street analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $720.00 to $1,189.00. On average, they anticipate the company's share price to reach $976.41 in the next year. This suggests a possible upside of 8.9% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.
How have REGN shares performed in 2024?: Regeneron Pharmaceuticals' stock was trading at $878.29 at the start of the year. Since then, REGN shares have increased by 2.1% and is now trading at $896.82.
View the best growth stocks for 2024 here.
When is Regeneron Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our REGN earnings forecast.
How can I listen to Regeneron Pharmaceuticals' earnings call?: Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Regeneron Pharmaceuticals' earnings last quarter?: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Friday, February, 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a trailing twelve-month return on equity of 17.61%. Regeneron Pharmaceuticals's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $10.96 EPS.
Read the conference call transcript.

What ETFs hold Regeneron Pharmaceuticals' stock?: ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA) and American CenturyFocused Dynamic Growth ETF (FDG).
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?: 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.
What other stocks do shareholders of Regeneron Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).
Who are Regeneron Pharmaceuticals' major shareholders?: Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Global Assets Advisory LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Perpetual Ltd (0.08%), Allspring Global Investments Holdings LLC (0.05%), Atwood & Palmer Inc. (0.04%) and State of Michigan Retirement System (0.03%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.
How do I buy shares of Regeneron Pharmaceuticals?: Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Regeneron Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More

This page (NASDAQ:REGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial